R A Bhujwala1, V L Bhargava, S Amatya
1Department of Microbiology, All India Institute of Medical Sciences, New Delhi.
This study looked at the role of C. trachomatis in pelvic inflammatory disease. Researchers tested 335 women diagnosed with PID for the presence of C. trachomatis antigen and IgG antibodies. They found that 35.22% had detectable antigen in their lower genital tract, and 56.11% had IgG antibodies, with 47.34% of those showing high antibody levels. Repeat testing on 37 patients showed a 40% increase in antibody titre. Doxycycline therapy was successful in 80% of cases. These findings suggest C. trachomatis is a significant cause of PID and highlight the importance of early diagnosis and treatment to prevent complications.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Pelvic inflammatory disease remains a significant health concern for women. Prior research has shown that multiple bacterial species contribute to PID. However, the role of specific pathogens in clinical outcomes remains unclear. No prior work had resolved the prevalence of C. trachomatis in PID cases. This gap motivated the need for a focused analysis. Some studies suggest that chlamydial infection may lead to ascending infections. Others have linked C. trachomatis to long-term reproductive complications. The need for accurate diagnostic markers persists. This paper's contribution centers on antigen and antibody detection rates.
Purpose Of The Study:
The study aimed to assess the involvement of C. trachomatis in PID. Researchers wanted to quantify antigen and antibody prevalence in diagnosed patients. They also sought to determine the effectiveness of doxycycline therapy. The motivation stemmed from the lack of clear diagnostic markers. No prior work had combined antigen detection with antibody titre changes. The team focused on a clinical cohort of 335 women. They aimed to correlate diagnostic findings with treatment outcomes. This approach allowed for a more complete understanding of C. trachomatis' role.
C. trachomatis antigen was found in 35.22% of PID patients, and IgG antibody in 56.11%.
Antigen was detected in lower genital tract samples, and IgG antibody levels were measured in serum.
To observe changes in antibody titre over time, indicating an active immune response.
Doxycycline therapy was used to assess treatment success, with an 80% success rate reported.
47.34% of patients with IgG antibodies had high titres.
Main Methods:
The researchers used antigen detection and serological testing. They collected lower genital tract samples from 335 patients. IgG antibody levels were measured in serum samples. Repeat testing was conducted on a subset of 37 patients. Doxycycline therapy was administered to assess treatment success. The study design included clinical diagnosis of PID as an inclusion criterion. No experimental interventions were performed. The team focused on correlating antigen presence with antibody responses.
Main Results:
C. trachomatis antigen was found in 35.22% of patients. IgG antibody was present in 56.11% of the cohort. Among these, 47.34% had high antibody titres. Repeat testing showed a 40% increase in antibody titre. The overall success rate of doxycycline therapy was 80%. These findings suggest a strong association between C. trachomatis and PID. The antigen detection rate supports the pathogen's role in disease. The antibody titre changes indicate an active immune response.
Conclusions:
The study suggests that C. trachomatis is a significant cause of PID. The high antigen and antibody detection rates support this claim. The 80% success rate of doxycycline therapy is promising. Early diagnosis may help prevent complications. The antibody titre changes indicate ongoing infection. These findings may inform clinical guidelines. The authors propose that routine screening could improve outcomes. They suggest further research on diagnostic accuracy and treatment protocols.
The authors suggest early diagnosis and treatment may prevent further complications of PID.